Serum Institute of India is the vaccine producer that will invest 50 million pounds ($68.24 million) in Oxford Biomedica, one of the COVID-19 vaccine manufacturers for drug major AstraZeneca, the British cell therapy firm said.
- India sees minimal impact from US trade policies, but risks persist: UBI Report
- Perplexity in Early Funding Talks at $18 Billion Valuation
- Toyota to Launch First India R&D Hub, Plans 1,000 Engineers & EV Expansion by 2027
- Trump Announces Upcoming US-Ukraine Minerals Deal
- Mazagon Dock, Goa Tie Up for AI-Based Disaster Management; Shares Fall 1%
The proceeds of the transaction will be used to fund the development of the fallow area at Oxbox, the group’s 84,000 sq. ft manufacturing facility based in Oxford, UK, into a flexible advanced manufacturing space and the validation of several independent cGMP suites, expected to come online in mid-2023.
